Morgan Stanley Mi Nk Therapeutics, Inc. Transaction History

Morgan Stanley

$1.27 Trillion
Q2 2024

A detailed history of Morgan Stanley transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 383 shares of INKT stock, worth $279. This represents 0.0% of its overall portfolio holdings.

Number of Shares

383

Previous 600 36.17%

Holding current value

$279

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 17, 2024	SELL	$0.87 - $1.56 $188 - $338	-217 Reduced 36.17%	383 $0
Q2 2024 Aug 14, 2024	SELL	$0.87 - $1.56 $188 - $338	-217 Reduced 36.17%	383 $0
Q1 2024 Oct 17, 2024	BUY	$0.84 - $1.12 $182 - $243	217 Added 56.66%	600 $0
Q1 2024 Aug 16, 2024	SELL	$0.84 - $1.12 $3,265 - $4,353	-3,887 Reduced 86.63%	600 $0
Q1 2024 May 15, 2024	SELL	$0.84 - $1.12 $3,265 - $4,353	-3,887 Reduced 86.63%	600 $0
Q4 2023 Aug 16, 2024	BUY	$0.88 - $1.21 $3,611 - $4,965	4,104 Added 1071.54%	4,487 $4,000
Q4 2023 Feb 13, 2024	SELL	$0.88 - $1.21 $3,176 - $4,368	-3,610 Reduced 44.58%	4,487 $4,000
Q3 2023 Nov 15, 2023	SELL	$1.1 - $2.09 $4,499 - $8,548	-4,090 Reduced 33.56%	8,097 $8,000
Q2 2023 Aug 14, 2023	BUY	$0.89 - $3.33 $10,846 - $40,582	12,187 New	12,187 $25,000
Q4 2022 Feb 14, 2023	SELL	$1.89 - $3.16 $1 - $3	-1 Reduced 2.38%	41 $0
Q3 2022 Nov 14, 2022	SELL	$1.19 - $3.4 $500 - $1,431	-421 Reduced 90.93%	42 $0
Q2 2022 Oct 27, 2022	BUY	$1.25 - $3.25 $466 - $1,212	373 Added 414.44%	463 $1,000
Q2 2022 Aug 15, 2022	BUY	$1.25 - $3.25 $466 - $1,212	373 Added 414.44%	463 $1,000
Q1 2022 Oct 27, 2022	SELL	$2.2 - $4.75 $820 - $1,771	-373 Reduced 80.56%	90 $0
Q1 2022 May 13, 2022	SELL	$2.2 - $4.75 $93,456 - $201,780	-42,480 Reduced 99.79%	90 $0
Q4 2021 Feb 14, 2022	BUY	$4.12 - $20.03 $175,388 - $852,677	42,570 New	42,570 $189,000

Others Institutions Holding INKT

# of Institutions

Shares Held

912K

Call Options Held

Put Options Held

View Full List

About MiNK Therapeutics, Inc.

Ticker INKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,775,100
Market Cap $24.7M
Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...

More about INKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account